✦ LIBER ✦

Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study

✍ Scribed by Zhaleh Khaleeli; Olga Ciccarelli; Francesco Manfredonia; Frederik Barkhof; Bruno Brochet; Mara Cercignani; Vincent Dousset; Massimo Filippi; Xavier Montalban; Chris Polman; Marco Rovaris; Alex Rovira; Jaume Sastre-Garriga; Machteld Vellinga; David Miller; Alan Thompson

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 90 KB
Volume: 63
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.21375

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Glatiramer acetate in primary progressiv

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Synovial membrane cytokine expression is

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort)

✍ Bruce W. Kirkham; Marissa N. Lassere; John P. Edmonds; Katherine M. Juhasz; Paul 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Effect of interferon-β1b on magnetic res

Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial

✍ D. H. Miller; P. D. Molyneux; G. J. Barker; D. G. MacManus; I. F. Moseley; K. Wa 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Influence of familial factors on radiolo

Influence of familial factors on radiologic disease progression over two years in siblings with osteoarthritis at multiple sites: A prospective longitudinal cohort study

✍ Botha-Scheepers, Stella A. ;Watt, Iain ;Slagboom, Eline ;Meulenbelt, Ingrid ;Ros 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## Abstract ## Objective The contribution of genetics to osteoarthritis (OA) progression is not known. To gain more insight into whether familial factors play a role in disease progression of OA, we analyzed familial aggregation of radiologic OA progression in a study of sibling pairs (the Genetic

Autoantibodies and microvascular damage

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis

✍ Martial Koenig; France Joyal; Marvin J. Fritzler; André Roussin; Michal Abrahamo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

## Abstract ## Objective To identify in patients with Raynaud's phenomenon (RP) independent markers that predict progression to definite systemic sclerosis (SSc) and to determine in patients with progression to SSc the type and sequence of microvascular damage and its relationship to SSc‐specific